weekly_roundup
BioTechSign Daily Catalyst Roundup - October 26, 2026
Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisOctober 26, 2026
Daily Biotech Catalyst Digest: October 26, 2026
ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| ITCI | Intra-Cellular Therapies | 100.0 | A | clinical activity 100% |
| DCPH | Deciphera Pharmaceuticals | 100.0 | A | clinical activity 100% |
| BGNE | BeiGene Ltd | 100.0 | A | publication signal 100%, clinical activity 100% |
| AKBA | Akebia Therapeutics | 87.2 | A | clinical activity 92%, short interest 50% |
| RGNX | REGENXBIO Inc | 86.4 | A | publication signal 100%, clinical activity 100%, short interest 70% |
| SRPT | Sarepta Therapeutics | 85.9 | A | clinical activity 100%, short interest 70%, dilution risk 48% |
Recent Grade-Change Queue
- NTLA (Intellia Therapeutics) currently grades D with a 45.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 79%.
- NKTR (Nektar Therapeutics) currently grades B with a 74.0/100 catalyst score. Main inputs: short interest 90%, clinical activity 75%, dilution risk 65%.
- CELZ (Creative Medical Technology Holdings, Inc.) currently grades D with a 42.4/100 catalyst score. Main inputs: dilution risk 83%, clinical activity 33%, short interest 10%.
- AIM (AIM ImmunoTech Inc.) currently grades D with a 37.2/100 catalyst score. Main inputs: dilution risk 75%, short interest 50%, clinical activity 46%.
- ALLO (Allogene Therapeutics) currently grades F with a 23.9/100 catalyst score. Main inputs: publication signal 100%, dilution risk 51%, short interest 50%.
- NRIX (Nurix Therapeutics) currently grades F with a 34.9/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 54%.
- GPCR (Structure Therapeutics) currently grades D with a 45.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, dilution risk 27%.
- CAPR (Capricor Therapeutics, Inc.) currently grades C with a 52.0/100 catalyst score. Main inputs: PDUFA timing 90%, short interest 90%, dilution risk 34%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.